Healthcare provider profile · identity verified

Stephen J Schnell, MD

Internal Medicine · PARMA, OH · NPI 1346347309

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	752	201
Amlodipine Besylate	Amlodipine Besylate	626	167
Losartan Potassium	Losartan Potassium	555	148
Levothyroxine Sodium	Levothyroxine Sodium	535	125
Enalapril Maleate	Enalapril Maleate	415	102
Metformin Hcl	Metformin Hcl	306	87
Pantoprazole Sodium	Pantoprazole Sodium	304	74
Simvastatin	Simvastatin	298	79
Hydrochlorothiazide	Hydrochlorothiazide	292	79
Lisinopril	Lisinopril	284	74
Furosemide	Furosemide	274	78
Omeprazole	Omeprazole	204	50
Sertraline Hcl	Sertraline Hcl	199	39
Metoprolol Succinate	Metoprolol Succinate	196	49
Tamsulosin Hcl	Tamsulosin Hcl	183	49
Atenolol	Atenolol	168	43
Metoprolol Tartrate	Metoprolol Tartrate	167	40
Pravastatin Sodium	Pravastatin Sodium	167	38
Glimepiride	Glimepiride	151	34
Azithromycin	Azithromycin	147	126
Eliquis	Apixaban	130	23
Alprazolam	Alprazolam	122	21
Allopurinol	Allopurinol	114	29
Potassium Chloride	Potassium Chloride	111	26
Synthroid	Levothyroxine Sodium	94	24
Rosuvastatin Calcium	Rosuvastatin Calcium	92	26
Lorazepam	Lorazepam	66	14
Torsemide	Torsemide	64	18
Clopidogrel	Clopidogrel Bisulfate	63	13
Lovastatin	Lovastatin	62	18
Escitalopram Oxalate	Escitalopram Oxalate	58	13
Gabapentin	Gabapentin	58	16
Ciprofloxacin Hcl	Ciprofloxacin Hcl	55	38
Mirtazapine	Mirtazapine	55	13
Warfarin Sodium	Warfarin Sodium	53	suppressed
Xarelto	Rivaroxaban	52	11
Trazodone Hcl	Trazodone Hcl	50	12
Albuterol Sulfate Hfa	Albuterol Sulfate	49	28
Montelukast Sodium	Montelukast Sodium	49	12
Ezetimibe	Ezetimibe	48	suppressed
Tramadol Hcl	Tramadol Hcl	48	14
Duloxetine Hcl	Duloxetine Hcl	46	suppressed
Methylprednisolone	Methylprednisolone	46	42
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	45	30
Clonazepam	Clonazepam	44	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Alendronate Sodium	Alendronate Sodium	43	12
Famotidine	Famotidine	42	11
Esomeprazole Magnesium	Esomeprazole Magnesium	40	suppressed
Meloxicam	Meloxicam	39	12
Oxybutynin Chloride Er	Oxybutynin Chloride	38	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	34	suppressed
Metformin Hcl Er	Metformin Hcl	32	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	30	suppressed
Spironolactone	Spironolactone	30	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Lactulose	Lactulose	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	21
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Finasteride	Finasteride	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Irbesartan	Irbesartan	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Ramipril	Ramipril	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Cephalexin	Cephalexin	17	14
Chlorthalidone	Chlorthalidone	17	suppressed
Diazepam	Diazepam	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	12
Sucralfate	Sucralfate	16	suppressed
Valsartan	Valsartan	16	suppressed
Amoxicillin	Amoxicillin	15	13
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Glipizide	Glipizide	13	suppressed
Ozempic	Semaglutide	13	suppressed
Scopolamine	Scopolamine	13	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Invokana	Canagliflozin	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error